New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
16:18 EDTSGENSeattle Genetics reports Q2 EPS (38c), consensus (26c)
Reports Q2 revenue $77.1M, consensus $77.97M.
10:23 EDTBCRC.R. Bard management to meet with JMP Securities
Subscribe for More Information
July 29, 2015
17:13 EDTISISIsis announces publication of Phase 2 clinical results from volanesorsen study
Isis Pharmaceuticals and Akcea Therapeutics, its wholly owned subsidiary, announced that the New England Journal of Medicine has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen, formerly ISIS-APOCIIIRx, in patients with very high to severely high triglycerides. This publication follows the December 2014 publication in the New England Journal of Medicine of the positive Phase 2 results from a clinical study of volanesorsen in patients with familial chylomicronemia syndrome. Volanesorsen is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics.
13:01 EDTKBIOKaloBios announces FDA clearance of IND application for KB003
KaloBios announced that the FDA has cleared the company's investigational new drug application for KB003, an anti-GM-CSF monoclonal antibody, in patients with chronic myelomonocytic leukemia, and that the IND is now active. The acceptance of this IND allows KaloBios to initiate an open-label Phase I study designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML patients. The study will consist of an accelerated dose escalation component starting at 200 mg and escalating up to 600 mg, followed by a cohort expansion of up to 13 additional patients to explore clinical activity at the selected dose level. Site initiation activities are underway, and the company anticipates that enrollment will begin later this year.
10:17 EDTKBIOKaloBios regains compliance with nasdaq minimum bid price requirement
Subscribe for More Information
July 28, 2015
16:11 EDTEXAMExamWorks sees Q3 revenue $202M-$208M, consensus $206.5M
Subscribe for More Information
16:05 EDTEXAMExamWorks raises FY15 revenue growth view to 4.5%-6.5% from 4%-6%
Subscribe for More Information
16:03 EDTEXAMExamWorks reports Q2 EPS (19c), consensus (21c)
Subscribe for More Information
July 27, 2015
10:40 EDTISIS, ACADIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
07:07 EDTISISIsis Pharmaceuticals announces results from ISIS-TTRRx study
Subscribe for More Information
July 24, 2015
16:22 EDTBCROn The Fly: Top stock stories for Friday
Subscribe for More Information
July 23, 2015
17:33 EDTBCRC.R. Bard sees Q3 EPS $2.21-$2.25, consensus $2.28
Subscribe for More Information
17:32 EDTBCRC.R. Bard raises FY15 EPS view to $9-$9.10 from $8.95-$9.05, consensus $9.02
16:29 EDTBCRC.R. Bard reports Q2 adjusted EPS $2.27, consensus $2.18
Subscribe for More Information
15:04 EDTBCRNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
19:26 EDTISISIsis Pharmaceuticals announces positive clinical data of ISIS-APO(a)Rx published
Subscribe for More Information
July 21, 2015
10:01 EDTEXAMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:27 EDTBCRFDA sent C.R. Bard warning letter after facility inspection
The FDA sent C.R. Bard a warning letter after inspecting the company's Peripheral Vascular facility. The letter stated in part, "FDA is aware that your firm submitted both in-vitro and in-vivo testing demonstrating the use of the Recovery Cone Removal System, Model RC-15 for removal of the Recovery Filter (K031328), the G2X Filter (K082305), the G2 Express Filter (K080668), and the G2 Filter (K073090). However, the Recovery Cone System, Model RC-15 was not included as part of the clearances for any of the aforementioned IVC filters. Therefore, your firm is marketing the Recovery Cone Removal System, Model RC-15 in the United States without marketing clearance or approval. Percutaneous retrieval systems, such as the Recovery Cone Removal System, Model RC-15, are regulated as manual surgical instruments intended for specialized use within a specific medical specialty, and thus require marketing authorization in order to be legally marketed in the United States." Reference Link
08:31 EDTEXAMExamWorks downgraded to Sell from Neutral at Goldman
Subscribe for More Information
07:13 EDTISISIsis Pharmaceuticals initiates Phase 1/2a clinical study of ISIS-HTT Rx
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use